BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Kelun Biotech Articulates Global Innovation Vision At J P Morgan Healthcare Conference

From January 12 to 15, 2026, the 44th J.P. Morgan Healthcare Conference (JPMHC) was held in San Francisco, California, USA. Dr. Ge Michael, President and C...

January 19, 2026 | News

Antengene Showcases Next Phase Of Global Innovation At J P Morgan Healthcare Conference

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, develop...

January 19, 2026 | News

Immunofoco CAR T Therapy IMC002 Posts Strong Responses In Advanced Gastric And Gej Cancers At Asco Gi 2026

Immunofoco, a clinical-stage biotechnology company advancing innovative CAR-T cell therapies for solid tumors, recently announced clinical data from ...

January 15, 2026 | News

Ractigen Doses First Patient In Phase Two Trial Of RAG 17 For SOD1 Mutated Als

The initial dosing occurred at Second Affiliated Hospital, Zhejiang University School of Medicine, under the leadership of Dr. Zhi-Ying Wu, head...

January 15, 2026 | News

Management of Relapsed/Refractory Multiple Myeloma

Doctors and researchers have made huge steps in treating this blood cancer lately. Yet, most people face a time when the cancer returns or stops responding...

January 14, 2026 | News

Lynk Pharmaceuticals Delivers Breakthrough Phase Three Win For Oral Rheumatoid Arthritis Therapy

Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical stage innovative drug development company focused on develop...

January 13, 2026 | News

Johnson And Johnson Amivantamab Combo Delivers 73% Response Rate In First Line Metastatic Colorectal Cancer

Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable res...

January 12, 2026 | News

Ascletis Secures US FDA IND Clearance For Phase II Diabetes Study Of Oral GLP One Candidate ASC30

-The Phase II study for diabetes is a 13-week, randomized, double-blind, placebo-controlled and multi-center study to evaluate the effi...

January 06, 2026 | News

2025 Drug Approvals, Decoded: What Every Biopharma Leader Needs to Know

At the centre of this momentum stood the U.S. Food and Drug Administration, whose 2025 approvals illustrated how medicine is moving decisiv...

December 29, 2025 | Analysis | By arcilla.fran@biopharmaapac.com

BioPharma Manufacturing Resilience: Lessons From Capacity Expansion and Supply Chain Resets from 2025

The year 2025 has marked a pivotal moment for the biopharmaceutical industry as it reckons with the aftershocks of a global pandemic and ongoing geopolitic...

December 24, 2025 | Analysis

Promontory Therapeutics Exceeds Interim Efficacy Bar In Thymoma Study With PT 112

Three of the first 10 patients with thymoma evaluated by RECIST have partial responses. Findings exceed protocol requirement of two re...

December 24, 2025 | News

Merck Secures World First Regulatory Approval For Pimicotinib In Rare Joint Tumour TGCT In China

First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER study In MANEUVER, pimicotinib significantl...

December 23, 2025 | News

Atom Therapeutics Secures FDA Approval To Advance Phase II Trial Of ABP 745 In Atherosclerosis

Atom Therapeutics, a clinical stage biotechnology company developing best-in-class treatments for inflammatory and metabolic diseases, today announced FDA ...

December 18, 2025 | News

AusperBio Reports 30% Functional Cure Rate With AHB 137 In Chronic Hepatitis B

AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a clinical-stage biotechnology company developing oli...

December 16, 2025 | Report

Stay Connected